We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Type Linked to Risk of COVID-19 Infection Severity

By LabMedica International staff writers
Posted on 04 Jan 2021
Identification of risk factors for contracting and developing serious illness following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount interest. More...
Development of COVID-19 is associated with age, sex, and comorbidities, such as cardiovascular diseases, although severe disease is not limited to these risk groups.

Blood group A and B glycosyltransferases also affect glycosylation in a large number of cell types, including epithelial cells in the respiratory tract and shed viral particles. A, B, and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.

Clinical Immunologists at the Odense University Hospital (Odense, Denmark) and their colleagues analyzed data in a retrospective cohort study, of over 840,000 individuals in Denmark who underwent testing by polymerase chain reaction for SARS-CoV-2 between February 27 and July 30, 2020. Most of those tested (56%) had available ABO and RhD blood group information. The team also used ABO and RhD data of 2,204,742 individuals not tested for SARS-CoV-2 as a reference. This corresponded to approximately 38% of the entire Danish population.

The scientists reported that of the 473,654 tested individuals who had a known blood group, 7,422 were positive for SARS-CoV-2 and 466,232 were negative. The positive and negative groups had similar proportions of men (32.9% versus 32%) and similar median ages (52 years versus 50 years). Among patients with SARS-CoV-2, considerably fewer (38.4%) had blood type O than other tested blood types. When excluding blood type O, they observed no significant differences among patients with blood types A, B and AB. They also observed no difference in the RhD group between positive cases and the reference population. The investigators reported relative risk (RR) for contracting SARS-CoV-2 of 0.87 for blood type O, 1.09 for blood type A, 1.06 for blood type B and 1.15 for blood type AB.

Torben Barington, MD, a Professor of Medicine and the senior author of the study, said, “ABO blood groups are increasingly recognized to influence susceptibility to certain viruses, including SARS-CoV-1 and norovirus. A, B and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.” The study was originally published on October 14, 2020 in the journal Blood Advances.

Related Links:
Odense University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.